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Edited by Vladimir SkulachevAbstract Coumarins have attracted intense interest in recent
years because they have been identiﬁed from natural sources,
especially green plants and have diverse pharmacological proper-
ties. In this study, we investigated whether 7,8-dihydroxy-4-
methylcoumarin (DHMC) caused apoptosis in A549 human
non-small cell lung carcinoma cells (NSCLC) and, if so, by what
mechanisms. Here, we show that, in A549 human NSCLC cells,
DHMC induces apoptosis through mitochondria-mediated cas-
pase-dependent pathway. Although an increase in the levels of
reactive oxygen species (ROS) was observed, pre-treatment with
antioxidant showed no protective eﬀect against DHMC-induced
apoptosis. In addition, our immunoblot data revealed that
DHMC treatment led to down-regulation of Bcl-xl, Bax, p21,
Cox-2, p53 and upregulation of c-Myc. Results in the present
study for the ﬁrst time suggest that DHMC induces apoptosis
in human lung A549 cells through partial inhibition of ERK/
MAPK signaling.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Lung cancer is the leading cause of male and female cancer
deaths worldwide and its incidence is increasing everyday. The
conventional treatment of lung cancer includes surgery, radia-
tion and chemotherapy. Various chemotherapy drugs, includ-
ing doxorubicin, 5-ﬂuorouracil, cisplatin, etoposide and
gemcitabine, have been used to treat lung cancer [1–3]. Unfor-
tunately, all of these anticancer drugs aﬀect not only patholog-
ical tumour cells, but also normal cells, especially bone
marrow cells or intestinal epithelia with high turnover rate,Abbreviations: DHMC, 7,8-dihydroxy-4-methylcoumarin; DCFH-DA,
dichlorodihydroﬂuorescein diacetate; HE, hydro ethidine; ROS,
reactive oxygen species; Asc, ascorbic acid; DiOC6, 3,3 0dihexyloxa-
carbocyaniniodode; MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide); MMP (Dwm), mitochondrial membrane
potential; ERK, extracellular signal-regulated kinase
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resection together with chemotherapy oﬀers the best hope for
a cure, the 5-year survival rate remains poor (<15%), even in
patients with earlier stages of the disease [4,5]. As each of these
therapies have limitations, hence new strategies are needed to
improve the treatment eﬃcacy of this fatal disease. Our
main thrust is on identiﬁcation of those bioactive molecules
which have the greatest potential for development into new
therapeutic products and to understand the mechanisms of ac-
tion of those bioactive molecules at the molecular and cellular
levels.
Coumarin is found in a variety of plants such as tonka bean,
lavender, sweet clover grass, and licorice, and also occurs in
food plants such as strawberries, apricots, cherries, and cinna-
mon. Coumarins and related compounds have been shown to
posses many biological activities such as antithrombotic [6],
antimicrobial activity [7], anti-tumorigenic [8–11]. Coumarin
derivatives have also been evaluated in treatment of human
immuno-deﬁciency virus, due to their ability to inhibit human
immunodeﬁciency virus integrase [12].
Earlier Koshy et al. [13] have studied the pro-oxidant
action of 7,8-diacetoxy-4-methylcoumarin (DAMC) and
DHMC on MDA-MB-468 and U-87 MG cell lines but till
date, there are no reports on the cytostatic and apoptotic
actions of DHMC in A549 human NSCLC cells. Thus the
main focus of this study was to explore the potential of the
coumarin compound, DHMC in view of apoptosis in NSCLC
cells.
Apoptosis is deﬁned as an active physiological process of cell
self-destruction with speciﬁc morphological and biochemical
changes in the nucleus and cytoplasm [14,15]. Agents that sup-
press the proliferation of malignant cells, by inducing apopto-
sis may represent a useful mechanistic approach to both
chemoprevention and chemotherapy of cancer. In this paper,
for the ﬁrst time, we examined the cytotoxic eﬀect of DHMC
in A549 human NSCLC cells. Herein, we showed that DHMC
induces apoptosis of A549 human NSCLC cells via mitochon-
dria-mediated mechanism with activation of caspase-9, -3 and
release of mitochondrial cytochrome c. In addition our ﬁnd-
ings also suggest that apoptosis induced by DHMC was reac-
tive oxygen species (ROS) independent and occurs by
downregulation of Bcl-xl, Bax, p21, p53, Cox-2, ERK/MAPK
and upregulation of c-Myc. The results indicate that DHMC
may provide a useful new therapeutic strategy for lung adeno-
carcinoma.blished by Elsevier B.V. All rights reserved.
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2.1. Test compounds and reagents
DMEM, penicillin/streptomycin was obtained from GIBCO BRL
Life Technologies, Rockville, MD, USA. Dimethyl sulfoxide (DMSO),
MEK1/2 inhibitor (U0126), ascorbic acid, (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) (MTT), trypsin, carbonyl
cyanide m-chlorophenylhydrazone, hydro ethidine (HE), 3,3 0dihexyl-
oxacarbocyaniniodode (DiOC6), dichlorodihydroﬂuorescein diacetate
(DCFH-DA), anti-c-Myc and Histopaque were purchased from Sigma
(St. Louis, MO, USA). DC protein assay was from Bio-Rad Labora-
tories, Hercules, CA, USA.
Fetal calf serum was purchased from Biological Industries, Kibbutz
Beit Haemek, Israel. DHMC was synthesized as detailed earlier and its
purity has been established on the basis of the spectral (1H, 13C NMR
and mass) data and its melting point [16].
Annexin V-FITC kit, Apoalert Cell fractionation kit, caspase-3 and
caspse-9 activity kits and anti-Cox-2 were from BD Biosciences Pharm-
ingen, San Diego, CA, USA. DeadEnd Colorimetric TUNEL System
and caspase-Glow 8 assay kit were from Promega, Madison, WI,
USA. Anti-Bcl-xl, anti-Bax, anti ERK/MAPK, anti-p-ERK/MAPK,
anti-p21, and anti-p53 were from Santa Cruz Biotechnology, CA,
USA. Anti-GAPDH and anti-b actin were from Imgenex, San Diego,
CA, USA.
2.2. Cell culture
A549 (NSCLC, lung adenocarcinoma), HepG2 (hepatocellular ade-
nocarcinoma), Hela (cervical carcinoma) and Hep2 (laryngeal carci-
noma) cells were obtained from National Center for Cell Science,
Pune, India and maintained in DMEM medium containing 10% (v/
v) fetal calf serum, penicillin (100 U/ml) and streptomycin (100 lg/
ml) in a humidiﬁed 5% CO2 atmosphere. Logarithmically growing cells
were used in all experiments. DHMC stock solutions were made up in
DMSO and stored at 20 C. Peripheral blood mononuclear cells
(PBMC) from healthy donors were isolated by density gradient centri-
fugation using Histopaque. The initial cell density for PBMC was
1 · 106 cells/ml.
Where indicated, ﬂow cytometric analysis and Western blot analysis
(described below) were done using the MEK1/2 inhibitor. U0126
(20 lM) in DMSO or an equivalent volume of DMSO as a control,
was added to the culture medium 30 min prior to the treatment. The
cells were then treated with DHMC (160 lg/ml) for 2, 4, 8, 12 and
24 h and taken for analysis.
2.3. Cell viability assay
A549, HepG2, Hela and Hep2 cells were grown in 96-well microtiter
plates and treated with diﬀerent concentrations (0–200 lg/ml) of
DHMC in triplicates. As controls, 0.1% DMSO treated cells (vehicle)
were included in each experiment. One hundred microliters of MTT
(5 mg/ml) was added to each well followed by incubation for 4 h at
37 C. The formazan precipitate was dissolved in 100 ll DMSO and
the absorbance was measured at 570 nm using an ELISA reader [17].
2.4. Flow cytometric analysis for cell cycle and apoptosis
For analysis of cell cycle distribution, 1 · 106 cells were harvested by
centrifugation, washed in phosphate-buﬀered saline (PBS), ﬁxed with
ice-cold 70% ethanol and treated with 1 mg/ml RNAse for 30 min.
Intracellular DNA was labeled with propidium iodide (50 lg/ml) and
analyzed using ﬂow cytometer (FACS Vantage Becton Dickenson,
CA, USA). Data were collected, stored and analyzed using CellQuest
software (Becton Dickinson, CA, USA). Surface exposure of phospha-
tidylserine in apoptotic cells was measured by Annexin V-FITC/PI
apoptosis detection kit I. FITC ﬂuorescence was analyzed by Cell-
Quest software (Becton Dickinson, CA, USA).
2.5. TUNEL assay
Apoptotic cells were visualized by the terminal deoxynucleotidyl
transferase mediated dUTP nick end labeling technique using the Dead
End Colorimetric TUNEL System [17].
2.6. Preparation of cell lysates and immunoblot analysis
Vehicle treated and DHMC treated cells were harvested after 24 h
and lysed in ice cold RIPA lysis buﬀer (Tris–HCl: 50 mM, pH 7.4 ,
NP-40: 1% , Na-deoxycholate: 0.25%, NaCl: 150 mM, EDTA:1 mM, PMSF: 1 mM, aprotinin 1 lg/ml, leupeptin 1 lg/ml and pepsta-
tin: 1 lg/ml, Na3VO4: 1 mM, NaF: 1 mM). The protein content in the
lysates was measured by DC protein assay. Protein (50–60 lg) was re-
solved on 12–15% SDS–PAGE and electroblotted onto PVDF mem-
brane. The membrane was then incubated in 3% BSA for 2 h
followed by overnight incubation with respective antibodies. After
washing, corresponding secondary antibody (horseradish peroxidase
conjugate or alkaline phosphatase conjugate) was added and incubated
for 2 h. After washing, the blots were developed either with NBT-BCIP
or DAB. Blots were scanned by light densitometry using AlphaImager
3400 (Alpha InnoTech Corporation, San Leandro, CA). The AlphaIm-
ager was then used to calculate the band intensities in each blot from
the digital picture of the membrane. Relative protein expression was
quantitated by alpha imager 3400 and normalized using b actin or
GAPDH [17].2.7. Detection of cytochrome c release
Cytosolic and mitochondrial extracts were prepared as described
[17]. In brief, cell pellets were homogenized in buﬀer (250 mM sucrose,
20 mM HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM
EDTA, 1 mM EGTA, 1 mM dithiothreitol, and 0.1 mM phenylmeth-
ylsulfonyl ﬂuoride). The cytosolic and mitochondrial fraction was
collected by centrifugation (15000 rpm for 30 min at 4 C) and sub-
jected to immunoblot analysis with a monoclonal antibody to cyto-
chrome c.2.8. Measurement of caspase-3, -8 and -9 activities
Caspase-3 activity was determined as described [17]. Brieﬂy, after
24 h of treatment, cells were lysed in lysis buﬀer (10 mM Tris–HCl;
10 mM NaH2PO4/Na2HPO4 pH 7.5; 130 mM NaCl; 1% Triton
-
X-100; 10 mM sodium pyrophosphate). 100 lg of total protein was
incubated with a synthetic tetrapeptide ﬂuorogenic substrate Ac-
DEVD-AMC in protease assay buﬀer (20 mM HEPES (pH 7.5);
10% glycerol; 2 mM DTT). Fluorescence of the released AMC was
measured spectroﬂuorometrically using an excitation wavelength of
380 nm and an emission wavelength range of 420–460 nm as described
[17]. One unit is deﬁned as the amount of enzyme required to release
1 pmol of AMC per min at 37 C.
For caspase-9 assay, cells were lysed in the similar manner. Total
protein (100 lg) was incubated with the colorimetric caspase-9 sub-
strate LEHD-pNA in an assay buﬀer supplied in the kit (BD Biosci-
ences Pharmingen, San Diego, CA, USA). The release of the
chromophore P-nitroanilide was quantitated by spectrophotometry
at a wavelength of 405 nm. The background controls (reactions where
no cell lysate or where no colorimetric substrate was added) were sub-
tracted from the experimental results before calculating the mean
absorbance.
Caspase 8 activity was measured by the ‘‘Caspase-Glow 8 assay kit’’
as described by the manufacturers (Promega). The assay provides a
proluminogenic caspase-8 substrate in a buﬀer system optimized for
caspase activity, luciferase activity and cell lysis (supplied with the
kit). The signal generated is proportional to the amount of caspase
activity present.2.9. Detection of intracellular reactive oxygen species generation and
mitochondrial membrane potential (Dwm)
It is well documented that HE and DCFH-DA have been used fre-
quently to monitor H2O2 and hydroxyl radical levels in cells [18]. The
cells were incubated with or without DHMC (160 lg/ml) for 24 h and
were then treated with 10 lMHE or 5 lMDCFH-DA 30 min prior to
harvesting. After incubation cells were washed with PBS and analyzed
by ﬂow cytometry [18].
In order to measure Dwm, 4 · 105 cells were labeled with the ﬂuoro-
chrome DiOC6, 40 nM for 30 min prior to harvesting and incubated at
37 C for 30 min in the dark. After incubation with the ﬂuorochrome,
cells were immediately analyzed by ﬂow cytometry in order to measure
ﬂuorochrome incorporation.2.10. Statistical analysis
This was performed with student’s two tailed t-test using SPSS (win-
dows version 7.5), values of P < 0.05 were considered statistically signif-
icant.
A. Goel et al. / FEBS Letters 581 (2007) 2447–2454 24493. Results
3.1. DHMC reduced cell viability of A549 cells but not of normal
peripheral blood mononuclear cells
First, to examine the cytotoxic eﬀect of DHMC on A549,
HepG2, Hela and Hep2, cells were treated with diﬀerent doses
and cell viability was measured using MTT assay. As shown in
Fig. 1A, 24 h treatment, the cytotoxic eﬀects were dose related
in each of the cell lines tested. IC50 value for A549 was 160 lg/
ml, for Hela IC50 was 180 lg/ml, for Hep2 and HepG2,
IC50 > 200 lg/ml. IC50 was lowest in A549 cells which was sim-
ilar to other coumarins reported in the literature [19,20]. Inter-
estingly, the IC50 concentration for A549 cells did not appear
to have inhibitory eﬀects on PBMCs. The lowest possible non-
toxic dosage of 160 lg/ml was ﬁxed for DHMC and further
experiments were carried out on A549 cells exposed to
160 lg/ml.
To further assess the cytotoxic eﬀect we did time–course
experiment. In A549 cells, till 8 h exposure of DHMC, no
obvious eﬀect could be found regardless of the dose of DHMC
(Fig. 1B). However, a trend of decrease of cell viability as the
dose of DHMC increased was observed after 12 h exposureFig. 1. Induction of apoptosis by DHMC. (A) Cytotoxicity evaluated by MT
with increasing concentrations of DHMC for 24 h. Each point is the mean of
response of A549 cells as evaluated by MTT assay. *P < 0.01 vs vehicle contr
treated group) or 160 lg/ml of DHMC. Each data represent means ± S.E.M.
AnnexinV-FITC binding in A549 cells. (i) Vehicle treated control, (ii) cells tr
curcumin for 24 h (positive control). (E) Left panel shows the representative m
DHMC for 24 h under light microscope and right panel shows the TUNEL
DHMC for 24 h.(Fig. 1B), a signiﬁcant decrease in cell viability was observed
in a dose dependent manner following 24 h exposure
(Fig. 1B). According to above results, exposure of DHMC at
160 lg/ml for 24 h induced much more signiﬁcant cytotoxic ef-
fect on A549 cells, thus these conditions were adopted in the
following experiments to investigate the mechanism related
to the DHMC induced cytotoxicity.
3.2. DHMC induces apoptotic cell death in A549 cells
Next, to investigate whether DHMC-induced cell death was
due to apoptosis, FACS analysis was performed. As shown in
Fig. 1C, treatment of A549 cells with DHMC resulted in
marked increase in accumulation of sub-G1 phase cells, i.e.,
40.76 ± 1.4% in DHMC as compared to 11.59 ± 1.7% in vehi-
cle treated cells thereby suggesting apoptotic cell death.
DHMC treatment showed that 43.41 ± 5% cells were in G0/
G1 phase as compared to 57.69 ± 2% cells in vehicle treated
cells. The percentage of cells in G2/M phase was decreased
from 10.39 ± 2% in vehicle treated cells to 4.21 ± 5% in cells
treated with DHMC (160 lg/ml) after 24 h of exposure. We
also observed decrease in the proportion of cells in S phase
from 4.3 ± 2% in vehicle treated cells to 2.12 ± 1% in cellsT assay after exposure of A549, Hela, Hep2, HepG2 and PBMCs cells
three replicates; bars represent the SEM. (B) Dose and time dependent
ol. (C) Cell cycle distribution of A549 cells with 0.1% DMSO (vehicle-
from three independent experiments. *P < 0.01 vs vehicle control. (D)
eated with 160 lg/ml of DHMC for 24 h, (iii) cells treated with 60 lM
orphology of A549 cells when exposed to 0.1% DMSO or 160 lg/ml of
staining of A549 cells when exposed to 0.1% DMSO or 160 lg/ml of
2450 A. Goel et al. / FEBS Letters 581 (2007) 2447–2454treated with DHMC (160 lg/ml) after 24 h of exposure. These
results demonstrate that DHMC decreases cell viability by
inducing apoptosis.
For further conﬁrmation annexin V-FITC assay was per-
formed. As shown in Fig. 1D, the percentage of apoptotic cells
increased to 49.16% in DHMC treated A549 cells after treat-
ment with 160 lg/ml of DHMC dose as compared to
4.31 ± 1.2% in vehicle treated cells. These results show quanti-
tatively and qualitatively that DHMC induces apoptosis in
A549 cells. The results of annexin V were also validated with
a positive control, curcumin (60 lM). Additionally, we also
did TUNEL assay. In Fig. 1E, left panel shows the representa-
tive morphology and right panel shows the TUNEL assay of
vehicle treated and DHMC treated A549 cells. Under light
microscope, vehicle treated A549 cells appeared to have nor-
mal features with round and homogenous nuclei while DHMC
treated cells were somewhat smaller than control cells in cellu-
lar size and exhibited the characteristic feature of apoptosis
such as the appearance of the apoptotic bodies. Treatment
with 160 lg/ml of DHMC for 24 h showed number of TU-
NEL-positive cells as compared to vehicle treated A549 cells
thereby indicating that DHMC treatment induces apoptosis
in A549 cells.
3.3. DHMC induces apoptosis in A549 cells through caspase-9
and caspase-3
For a direct examination of the involvement of caspases in
DHMC-induced apoptosis, activity of caspase-3, -8 and -9
was examined using ﬂuorogenic, luminogenic and colorimetric
substrates. Results shown in Fig. 2 demonstrate that DHMC
treatment increased the activity of caspase-3 by 3-fold
(P = 0.004) and caspase-9 activity by 1.49-fold (P < 0.05) as
compared to vehicle treated cells. Interestingly, caspase-8
activity in vehicle treated and DHMC treated cells remained
unaﬀected. Increased caspase-8 activity was observed in cells
treated with TNFa (positive control data not shown).
3.4. DHMC induces apoptosis in A549 cells by mitochondrial
pathway
To look for the mitochondrial involvement, disruption of
mitochondrial membrane potential (Dwm), generation ofFig. 2. Involvement of caspase activation in DHMC induced apop-
tosis. A549 cells were treated with 160 lg/ml DHMC for 24 h. Extracts
from vehicle-treated (0.1% DMSO) or DHMC treated cells were
assayed for caspase-3 activity using a synthetic tetrapeptide ﬂuorogenic
substrate Ac-DEVD-AMC; caspase-9 activity using colorimetric
caspase-9 substrate LEHD-pNA; caspase-8 activity using a lumino-
genic substrate using LETD sequence. Each data represent mean-
s ± S.E.M. from four independent experiments. *P < 0.01 compared to
vehicle control.ROS and release of mitochondrial cytochrome c in A549 cells
was investigated by ﬂow cytometry and immunoblotting. As
indicated in Fig. 3A, as compared to controls, approximately
45% cells shifted towards left thereby indicating that the
DHMC treatment induced a disruption of Dwm. In contrast,
administration of DHMC resulted in a right shift of the
DCFH-DA and HE ﬂuorescence curves (48% cells shifted to-
wards right as compared to vehicle treated controls), indicating
the increase in ROS generation.
Next cytochrome c was detected in the cytoplasmic and
mitochondrial fraction by immunoblot analysis. As shown in
Fig. 3B (left panel), the relative density of cytochrome c in
the cytosol of the cells treated with DHMC (24 h) was in-
creased by 1.18-fold (P = 0.020) as compared to the vehicle
treated cells. Signiﬁcant amount of cytochrome c was present
in the mitochondria in vehicle-treated cells. Fig. 3B, right panel
shows the immunoblot for COX IV (Mitochondrial Loading
Control). Loading was also normalized using b-actin antibody.
These data suggest that DHMC treatment causes cytochrome
c release from mitochondria.3.5. DHMC induced apoptosis in A549 cells cannot be reversed
by antioxidants
Since we observed an increase in ROS generation during
DHMC treatment of cells, we examined the cell viability and
percentage apoptosis in vehicle treated and DHMC-treated
cells in the presence and absence of antioxidants. As shown
in Fig. 4A, pre-treatment with ascorbic acid (Asc, 300 lM)
for 2 h did not show any signiﬁcant change on the viability
of DHMC-treated cells (compare columns 2 and 3). Similarly,
no protective eﬀect against DHMC-induced apoptosis was ob-
served by annexin V-FITC assay (Fig. 4B, compare columns 2
and 3). Similar ﬁndings were also observed when we pre-trea-
ted the cells with N-acetyl cysteine (NAC, from 0.3 mM to
1 mM) (data not shown). These data suggest that DHMC-in-
duced apoptosis is independent of ROS production in A549
cells and oxidative stress may not be playing any role in
DHMC induced apoptosis.3.6. DHMC induces apoptosis by modulating apoptosis related
proteins
To gain further insights into the molecular events associated
with DHMC-induced apoptosis, the expression of apoptosis-
related and survival-related proteins was detected by immuno-
blotting. Results of immunoblot analysis (Fig. 5A and B) in
this study showed that 24 h treatment with DHMC decreased
the expression of Bcl-xl by 1.54-fold (P = 0.025), Bax by 1.72-
fold (P = 0.014), p53 by 1.34-fold (P = 0.020), Cox-2 by 1.37-
fold (P = 0.025) and p21 by 1.27-fold (P = 0.017) as compared
to vehicle treated cells. We also observed that 24 h treatment
with DHMC increased the expression of c-Myc by 1.7-fold
(P = 0.031), as compared to vehicle treated cells.
Next, we investigated ERK/MAPK signaling in A549 cells in
response to DHMC. Our time–course experiment (Fig. 5C) for
immunoblot analysis of equal amounts of protein from vehicle
treated and DHMC treated A549 cells shows signiﬁcant de-
crease of p-ERK at 12 h (1.2-fold decrease, P = 0.012) and
24 h (1.6-fold decrease, P = 0.018), respectively. Equal protein
amount in diﬀerent lysates was ascertained by immunoblotting
of parallel blot with b-actin antibody. Because the activation
of the ERK/MAPK pathway has been associated with anti-
Fig. 3. A549 cells were vehicle-treated (0.1% DMSO) or treated with 160 lg/ml DHMC for 24 h. (A) Dwm and ROS generation. Thirty minutes prior
to harvesting, cells were incubated with 40 nM DiOC6 or 5 lM DCFH-DA or 10 lM HE. After incubation, cells were harvested, and change in
ﬂuorescence was measured using ﬂow cytometry. The mitochondrial uncoupler cyanide m-chlorophenylhydrazone (mClCCP, 50 lM) is used
routinely for validation of measurements. (B) Mitochondrial cytochrome c release. Cytosolic fraction was isolated and the content of cytochrome c
was examined by immunoblot analysis using anti-cytochrome c antibody. Cytochrome c oxidase subunit IV is used as a loading control and excludes
mitochondrial contamination in the cytosol. The data shown are the representatives of three independent experiments. P value = 0.020.
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this pathway could modulate sensitivity to the drug. To verify
this hypothesis, we used U0126, a speciﬁc inhibitor of MEK1/2
[21]. U0126 caused substantial inhibition of ERK1/2 phos-
phorylation from 2 h (data not shown) to 24 h after treatment
(Fig. 5C). Total ERK1/2 protein levels were not decreased in
U0126-treated compared with control lysates (Fig. 5C). Our
time–course experiment (Fig. 5D) of U0126 revealed that the
U0126 treatment (20 lM) increased some basal apoptosis,
and potentiated the apoptotic eﬀect of DHMC. U0126 treat-
ment induced 5.3% apoptosis at 2 h, 8.2% apoptosis at 4 h,
10.45% apoptosis at 8 h, 15.7% apoptosis at 12 h and 16.8%
apoptosis at 24 h, respectively. DHMC alone showed 6%
apoptosis at 2 h, 10% apoptosis at 4 h, 15% apoptosis at 8 h,
25% apoptosis at 12 h and 35% apoptosis at 24 h. Pretreatment
of A549 cells with U0126 prior to DHMC treatment showed
70% apoptosis at 2 h and this eﬀect was more or less consistenttill 24 h (75.2%). Our results suggest that ERK1/2 inactivation
by U0126 lowered the apoptotic threshold of A549 cells for
DHMC as is evident by increased percentage of apoptosis
(70–75.2%) even at earlier time points (2, 4, and 8 h) as com-
pared to DHMC alone (6–15.7%).4. Discussion
Search for new chemopreventive and antitumor agents that
are more eﬀective but less toxic has kindled great interest in
phytochemicals. Coumarin is one such compound which was
used in this study. No adverse eﬀects of coumarin have been
reported in humans using doses up to 7 g daily, after two
weeks of continued treatment [22]. The main focus of this
study was to explore the potential of coumarin compound,
DHMC in relation to apoptosis.
Fig. 4. A549 cells were pretreated with 300 lM of ascorbic acid for 2 h
and then treated with vehicle (0.1% DMSO) or with 160 lg/ml DHMC
for 24 h. (A) Cell viability was analyzed using MTT assay. (B) Annexin
V-FITC assay was used to estimate percentage apoptosis. Columns: (1)
Control A549 cells, (2) DHMC treated Cells, (3) DHMC + Asc
(pretreated for 2 h) (4) Asc. *P < 0.01 and **P < 0.001 compared to
vehicle control.
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that DHMC induced A549 cell apoptosis in a dose-dependent
and time-dependent manner. More importantly, in our study
PBMC showed very less sensitivity to DHMC at various con-
centrations (0–200 lg/ml). Since our observations with PBMCFig. 5. (A) Eﬀect of DHMC on the protein expression of Bcl-xl, Bax, p53, p
were treated with vehicle (0.1% DMSO) or with 160 lg/ml DHMC for 24 h
SDS–PAGE followed by immunoblot analysis using speciﬁc antibodies and
conjugated antibodies. Details are described in Section 2. GAPDH was used a
in each lane. Data are representative of a typical experiment repeated three tim
data shown are the representatives of three independent experiments. *P < 0
with DHMC and MEK1/2 inhibitor U0126 on ERK activation. Cells were tre
(60 lg of total protein) were separated by electrophoresis, transferred to P
antibody. Protein contents were normalized using b-actin. Data are represen
(D) Time–course for induction of apoptosis in presence or absence of DH
estimated by Annexin V-FITC/PI apoptosis detection kit I (BD Bioscience
(Becton Dickinson). P < 0.05. (*) vs vehicle control, (+) vs DHMC, (·) vs Uexposed to high concentrations of the coumarins compounds
showed no cell death, induction of apoptosis by DHMC ap-
pears to be selective for cancer cells.
Our results indicate that DHMC-induced apoptosis in A549
human NSCLC cells was accompanied by down-regulation of
Bcl-xl (anti-apoptotic), decrease of the mitochondrial mem-
brane potential thus leading to cytochrome c release from
the mitochondria and activating caspase-9 and -3. In conjunc-
tion to our ﬁndings, it has been noticed in many in vitro
systems that apoptosis is associated with downregulation of
Bcl-xl, loss of mitochondrial membrane potential, which may
correspond to the opening of an outer membrane pore (perme-
ability transition pore) and this event has been suggested to be
responsible for cytochrome c release into cytosol from mito-
chondria [23–30]. Further in our study there appears a direct
activation of the mitochondrial pathway without involvement
of caspase-8. There are reports similar to our ﬁndings in the lit-
erature [31,32]. The present study also provides the evidence
that DHMC induces apoptosis through ROS independent
pathway since no protective eﬀect against DHMC-induced
apoptosis was observed in presence of antioxidant as assessed
by annexin V-FITC assay and MTT assay. Consistent to our
ﬁndings, Ko et al. [33] reported that apoptosis induced by
myricetin occurs through mitochondria -dependent, ROS-
independent pathway.
Apoptosis is a complex phenomenon where several genes are
involved in the regulation of apoptosis. Therefore in order to
better understand the molecular basis of DHMC-induced
apoptosis, the expression of p53, p21, Bax, ERK/MAPK,21, c-Myc, and Cox-2 in A549 cells. 2.5 · 105 cells/well of 6-well plate
. Total cell lysates were prepared and protein (50 lg) was subjected to
secondary horseradish peroxidase-conjugated or alkaline phosphatase
s internal control to ensure that equal amounts of proteins were loaded
es with similar results. (B) Densitometric analysis of immunoblot. The
.01 compared to vehicle control. (C) Eﬀect of treatment of A549 cells
ated with 160 lg/ml of DHMC for diﬀerent time points. The cell lysates
VDF membrane and probed with anti-p-ERK1/2 and anti-ERK1/2
tative of a typical experiment repeated three times with similar results.
MC and MEK1/2 inhibitor U0126. The induction of apoptosis was
s Pharmingen) and results were analyzed using CellQuest software
0126.
A. Goel et al. / FEBS Letters 581 (2007) 2447–2454 2453Cox-2 and c-Myc was investigated by immunoblot analysis.
p53 is a transcription factor that can induce either cell growth
arrest or apoptosis. There are reports in the literature which
show that apoptosis can occur in p53 dependent or indepen-
dent manner by regulating its target genes through binding
to DNA consensus sequence and activating the promoters of
its downstream genes (p21 and Bax) [34,35]. In our study, we
observed that treatment of A549 cells with DHMC leads to
down regulation of p53 levels. Since in our results we also ob-
served down regulation of Bax and p21 after DHMC treat-
ment it seems that in this system apoptosis occurs by p53
dependent pathway. Next, we propose that in our study c-
Myc might be playing a decisive role in the apoptosis induced
by DHMC either by acting as sensitizer/or apoptosis inducer
as our immunoblot results show that DHMC induces apopto-
sis by upregulating c-Myc protein. Since, we also observed
cytochrome c release and increased c-Myc expression; this
could be one of the mechanisms of DHMC induced apoptosis.
There are reports similar to our ﬁndings in the literature [36].
Nevertheless, further study is needed to elucidate the precise
role of c-Myc and p53 in DHMC-induced apoptosis. In the
present study, we also found that DHMC induces apoptosis
by ERK1/2 reduction and by down regulation of Cox-2. These
results are in accordance with the well known concept that
inhibition of MAPKs is likely to result in suppression of
inﬂammatory mediators, which in turn leads to the desired
therapeutic eﬀects [37].
In conclusion, mitochondria-dependent ROS-independent
apoptosis indicated by sequential events including reduction
of the mitochondrial potential, inhibition of Bcl-xl expression,
cytochrome c release from mitochondria to the cytosol, and
activation of caspase-9 and -3 enzymes was identiﬁed in the
present study. Results presented in this report also demon-
strate that DHMC induced apoptosis of human A549 cells
may be associated with partial inhibition of ERK/MAPK sig-
naling thereby suggesting a crosstalk between the two path-
ways. We believe that our data should contribute to the
development of DHMC or related drugs as potential cancer
chemotherapeutic or chemopreventive agents for the treatment
of NSCLC. However, future in vivo animal studies should help
determine its therapeutic eﬃcacy in treatment of NSCLC
which are otherwise resistant to chemotherapy.
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